Long
Buy $SRNE - NRPicks 07 Mar
Sorrento Therapeutics, Inc. is a commercial and clinically staged biopharmaceutical company, developing therapies for cancerous, autoimmune, inflammatory, viral and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex.
The company has been constantly adding new options to its bulky pipeline and has made two notable additions in the last month. Sorrento and its subsidiary Scilex are signing an exclusive licensing agreement with Aardvark Therapeutics to treat the post Covid chrononic chondrome.
The last move is that Sorrento is buying the outstanding assets of ANP Technologies for a total of $100 million, this acquisition will increase the additional capacity to produce COVID test kits and provide the know-how to optimize the test through the improvement of detection capabilities, thus conferring greater sensitivity and specificity".
Technical:
MACD Level (12, 26) 1.57
Low levels of RSI 35.78 Oversold
MA200 rebound
Price below MA 50 and MA100
The company has been constantly adding new options to its bulky pipeline and has made two notable additions in the last month. Sorrento and its subsidiary Scilex are signing an exclusive licensing agreement with Aardvark Therapeutics to treat the post Covid chrononic chondrome.
The last move is that Sorrento is buying the outstanding assets of ANP Technologies for a total of $100 million, this acquisition will increase the additional capacity to produce COVID test kits and provide the know-how to optimize the test through the improvement of detection capabilities, thus conferring greater sensitivity and specificity".
Technical:
MACD Level (12, 26) 1.57
Low levels of RSI 35.78 Oversold
MA200 rebound
Price below MA 50 and MA100
Trade closed: target reached
15 Mar
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.